Brief: STADA And Xbrane Weigh Options For Ranibizumab Biosimilar Candidate

Xbrane Biopharma AB

25/07/2023 07:09

July 25 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * STADA AND XBRANE WEIGH OPTIONS FOR RANIBIZUMAB BIOSIMILAR
CANDIDATE
    * STADA AND XBRANE CONSIDER OPTIONS, INCLUDING OUT-LICENSING
FOR
RANIBIZUMAB BIOSIMILAR CANDIDATE IN NORTH AMERICA
    * PREVIOUS COMMERCIAL LICENSE AGREEMENT WITH BAUSCH + LOMB
DISCONTINUED BY MUTUAL CONSENT

Source text for Eikon:  ID:nMFN1pvs8y 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))